The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase I study of DI17E6, a novel de-immunized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer (CRPC) with bone metastases after chemotherapy.
M. Wirth
Consultant or Advisory Role - Merck
A. Heidenreich
No relevant relationships to disclose
J. E. Gschwend
No relevant relationships to disclose
T. Gil
No relevant relationships to disclose
S. Zastrow
No relevant relationships to disclose
M. Laniado
No relevant relationships to disclose
L. Bernard
Employment or Leadership Position - Merck Serono (U)
T. Vardar
Employment or Leadership Position - Merck Serono
W. Uhl
Employment or Leadership Position - Merck KGaA (U)
H. Lannert
Employment or Leadership Position - Merck KGaA (U)